Palliative External Beam Thoracic Radiation Therapy of Non-Small Cell Lung Cancer

  • Stein Sundstrøm
Part of the Medical Radiology book series (MEDRAD)


About two-thirds of patients with non-small cell lung cancer are diagnosed with incurable disease and are usually treated with a palliative intent. Palliative radiotherapy is defined as radiotherapy given with less than radical doses. Although a large variation in treatment schedules considering dose, fractionation, and overall treatment time are used, usually a dose 50 Gy is considered as palliative. Given the palliative intent of the radiotherapy with the goal of reducing tumour-related symptoms, the radiotherapy should be simple to set up, to perform, and less time-consuming for the patient. If high-dose palliative fractionated radiotherapy is planned a normal setup margin defining GTV and CTV/PTV is recommended including the tumour and disease-related nodes. When low-dose radiotherapy is planned, the treated volume should include the symptomatic part of the tumour.Most studies show that the effect on symptoms and palliative effect is similar regardless of dose and fractionation. A trend of more rapid relief of symptoms in favour of hypofractionation is observed. Though no major difference in median survival is observed, some patients with localised stage III disease may have better survival with a protracted high-dose schedule. Acute toxicity with dysphagia is mild, temporary, and manageable. Late toxicity is rare and sporadic with low severity. Palliative thoracic radiotherapy should not be administrated to patients without symptoms present.


Palliative Radiotherapy Palliative Intent Intrathoracic Tumour Poor Prognostic Group Hypofractionated Schedule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abratt RP, Shepherd LJ, Mameena Salton DG (1995) Palliative radiation for stage 3 non-small cell lung cancer. A prospective study of two moderately high dose regimens. Lung Cancer 13:137–143PubMedCrossRefGoogle Scholar
  2. Bezjak A, Dixon P, Brundage M et al (2002) Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys 54:719–728Google Scholar
  3. Bradley JF, Ieumwananonthachai N, Purdy JA et al (2002) Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 52:49–57PubMedCrossRefGoogle Scholar
  4. Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer. Chest 122:1037–1057PubMedCrossRefGoogle Scholar
  5. Dehing-Oberije C, de Ruysscher D, van der Weide H et al (2008) Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 70:1039–1044PubMedCrossRefGoogle Scholar
  6. Erridge SC, Gaze MN, Price A et al (2005) Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clin Oncol 17:61–67CrossRefGoogle Scholar
  7. Fairchild A, Harris K, Barnes E et al (2008) Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 26:4001–4011PubMedCrossRefGoogle Scholar
  8. Falk S, Girling DJ, White RJ et al (2002) Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ 325:465–468PubMedCrossRefGoogle Scholar
  9. Hopwood P, Stephens RJ (1995) Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. Br J Cancer 71:663–666CrossRefGoogle Scholar
  10. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE (2010) Radiation dose-volume effects in the spinal cord. Int J Rad Oncol Biol Phys 76:suppl S42–S49Google Scholar
  11. Kramer G, Wanders SL, Noordijk EM et al (2005) Results of the Dutch National Study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer. J Clin Oncol 13:2962–2970CrossRefGoogle Scholar
  12. Lester JF, Macbeth FR, Toy E, Coles B et al (2006) Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev 18(4):CD002143Google Scholar
  13. Lutz S, Norrell R, Bertucio C et al (2001) Symptom frequency and severity in patients with metastatic or locally recurrent lung cancer: a prospective study using Lung Cancer Symptom Scale in a Community Hospital. J Palliat Med 4:157–165PubMedCrossRefGoogle Scholar
  14. Mac Manus MP, Matthews JP, Wada M et al (2005) Unexpected long-term survival after low-dose palliative radiotherapy for nonsmall cell lung cancer. Cancer 116:1110–1116Google Scholar
  15. MacBeth F, Wheldon TE, Girling DJ et al (1996) Radiation myelopathy: estimates of risk in 1,040 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. The Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) 8:176–181CrossRefGoogle Scholar
  16. Maher EJ, Coia L, Duncan G et al (1992) Treatment strategies in advanced and metastatic lung cancer: differences in attitude between the USA, Canada and Europe. Int J Radiat Oncol Biol Phys 23:239–244PubMedCrossRefGoogle Scholar
  17. Medical Research Council Lung Cancer Working Party (1992) A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small cell lung cancer (NSCLC) and poor performance status. Br J Cancer 65:931–941Google Scholar
  18. Medical Research Council Lung Cancer Working Party (1996) Randomised trial of palliative 2-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Clin Oncol 8:167–175Google Scholar
  19. MRC Lung Cancer Working Party (1991) Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Br J Cancer 63:265–270CrossRefGoogle Scholar
  20. Nestle U, Nieder C, Walter K et al (2000) A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs conventionally fractionated 60 Gy: results of a randomized equivalence study 48:195–203Google Scholar
  21. NSCLC Meta-analysis collaborative group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26:4617–4625Google Scholar
  22. Perez CA, Stanley K, Grundy G et al (1982) Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Cancer 50:1091–1099PubMedCrossRefGoogle Scholar
  23. Rees GJG, Devrell CE, Barley VL et al (1997) Palliative radiotherapy for lung cancer: two versus five fractions. Clin Oncol (R Coll Radiol) 9:90–95CrossRefGoogle Scholar
  24. Reinfuss M, Glinski B, Kowalska T et al (1999) Radiothérapie du cancer bronchique non á petites cellules de stade III inopérable asymptomatique. Résultats définitifs d’un essai prospectif randomisé (240 patients). Cancer Radiother 3:475–479PubMedCrossRefGoogle Scholar
  25. Reinfuss M, Mucha-Malecka A, Walasek T et al (2011) Palliative thoracic radiotherapy in non-small cell lung cancer. An analysis of 1,250 patients. Palliation of symptoms, tolerance and toxicity. Lung Cancer 71:344–348PubMedCrossRefGoogle Scholar
  26. Senkus-Konefka E, Dziadziuszko R, Bednaruk-Mlynski E et al (2005) A prospective randomised study to compare two palliative radiotherapy schedules for non-small-cell cancer (NSCLC). Br J Cancer 92:1038–1045PubMedCrossRefGoogle Scholar
  27. Simpson JR, Francis ME, Perez-Tamayo R et al (1985) Palliative radiotherapy for inoperable carcinoma of the lung: final report of a RTOG multi-institutional trial. Int J Radiat Onc Biol Phys 11:751–758CrossRefGoogle Scholar
  28. Sundstrøm S, Bremnes R, Aasebø U et al (2004) Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol 22:801–810PubMedCrossRefGoogle Scholar
  29. Sundstrøm S, Bremnes R, Brunsvig P et al (2005) Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study. Radiother Oncol 75:141–148CrossRefGoogle Scholar
  30. Sundstrøm S, Bremnes R, Brunsvig P et al (2006) Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy? J Thorac Oncol 1:816–824PubMedCrossRefGoogle Scholar
  31. Teo P, Tai TH, Choy D et al (1987) A randomized study on palliative radiation therapy for inoperable non small cell carcinoma of the lung. Int J Radiat Onc Biol Phys 14:867–871Google Scholar
  32. Yan S, Sun X Li MH et al (2007) A randomized study of involved field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III non small cell lung cancer. Am J Clin Oncol 30:239–244CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.St Olav University HospitalTrondheimNorway

Personalised recommendations